Log in to search using one of your social media accounts:

 

Hikma, Vectura in dispute with FDA over generic Advair
LONDON (Reuters) - Hikma and its partner Vectura are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S. market, delaying any eventual approval. (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

GlaxoSmithKline breathes easier as U.S. approves triple lung drug
LONDON (Reuters) - U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair. (Source: Reuters: Health)
Source: Reuters: Health - September 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

A Case of Worsening Dyspnea and Cough
Bob is a 72-year-old male, with a 40-pack-year smoking history. He quit about 8 years ago, when severe COPD was diagnosed. Until last year, he had been stable on his regimen of Advair 250/50 and Spiriva Handihaler, other than an occasional “bronchitis,” usually treated with an antibiotic and/or steroids. Over the past year or so, however, he has noticed a marked turn for the worse. He no longer can walk up the steps in his house without stopping and gasping for breath. (Source: ConsultantLive)
Source: ConsultantLive - August 22, 2017 Category: Internal Medicine Authors: Jonathan Ilowite, MD Tags: Respiratory Diseases Source Type: news

Mylan revises earnings guidance, defers product launches to 2018
Mylan NV on Wednesday said it is deferring all major U.S. launches from its full-year 2017 financial guidance to 2018, citing ongoing challenges and the uncertain U.S. regulatory environment. As a result, the pharmaceutical giant expects to deliver total revenues ranging between $11.5 billion and $12.5 billion and adjusted earnigns per share between $4.30 and $4.70. The product launches include generic versions of Advair and Copaxone. Mylan (Nasdaq:MYL) included the announcement in its quarterly… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 9, 2017 Category: Pharmaceuticals Authors: Patty Tascarella Source Type: news

Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus
Novartis (NYSE:NVS) unit Sandoz said today that the FDA has accepted the abbreviated new drug application for its generic version of Advair Diskus. The fluticasone propionate/salmeterol device is designed to treat asthma in patients ages 4 and older, as well as provide maintenance treatment of airflow obstruction and reduce exacerbations in patients with chronic obstructive pulmonary disease. Get the full story at our sister site, Drug Delivery Business News. The post Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat Amgen Novartis sandoz Source Type: news

US FDA issues CRL to Hikma ’s generic version of GSK’s Advair Diskus
Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its generic version of GlaxoSmithKline's Advair Diskus (fluticasone propionate and s … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

GSK wins Advair reprieve as second generic falters
Hikma and Vectura shares fall as US FDA withholds approval for lung drug substitute (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 11, 2017 Category: Pharmaceuticals Source Type: news

GSK dodges bullet after another generic Advair competitor is denied
GlaxoSmithKline (NYSE:GSK) will not likely face generic competition to its lung drug Advair in the US this year. Yesterday, the FDA denied the application for a 2nd generic competitor. Hikma Pharmaceuticals (LON:HIK) disclosed today that the FDA decided not to approve its version of the inhaled asthma treatment, due to “major” problems with the application. This comes on the heels of Mylan‘s (NSDQ:MYL) announcement in March that the federal watchdog delayed approval of its Advair generic. Thanks to these 2 rejections, industry analysts believe that the threat of generic competition has...
Source: Mass Device - May 11, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Hikma Pharmaceuticals PLC Mylan Source Type: news

GSK escapes Advair hit for now as second generic bid fails
LONDON (Reuters) - GlaxoSmithKline is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent form of the medicine was turned down by U.S. regulators. (Source: Reuters: Health)
Source: Reuters: Health - May 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Teva's new asthma inhaler poses first competition for GSK's Advair
(Reuters) - Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair. (Source: Reuters: Health)
Source: Reuters: Health - April 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Teva launches AirDuo RespiClick, generic inhaled asthma therapies
Teva Pharmaceutical (NYSE:TEVA) said today that it launched the AirDuo RespiClick inhalation therapy and its authorized generic in the U.S. for asthma patients who are uncontrolled on an inhaled corticosteroid. AirDuo RespiClick and the generic are fixed-dose combination therapies contained fluticasone propionate and salmeterol – the same active ingredients as Advair. The therapies are delivered using Teva’s breath-activated RespiClick inhaler. Get the full story at our sister site, Drug Delivery Business News. The post Teva launches AirDuo RespiClick, generic inhaled asthma therapies appeared first on Mas...
Source: Mass Device - April 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Teva Pharmaceuticals Source Type: news

FDA Declines to Approve Mylan's Generic Of GSK's Advair for Now FDA Declines to Approve Mylan's Generic Of GSK's Advair for Now
Mylan NV said on Wednesday the U.S. Food and Drug Administration declined to approve its generic version of GlaxoSmithKline Plc's blockbuster Advair asthma treatment, but provided no details of the agency's concerns or how long the product might be delayed.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 31, 2017 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

GSK's new CEO gets short-term win from generic Advair delay
LONDON (Reuters) - GlaxoSmithKline's new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan's copy of the blockbuster lung inhaler. (Source: Reuters: Health)
Source: Reuters: Health - March 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA declines to approve Mylan's generic of GSK's Advair for now
(Reuters) - Mylan NV said on Wednesday the U.S. Food and Drug Administration declined to approve its generic version of GlaxoSmithKline Plc's blockbuster Advair asthma treatment, but provided no details of the agency's concerns or how long the product might be delayed. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Mylan shares down -3% after FDA rejects Advair generic
Shares in Mylan (NSDQ:MYL) dropped -3% to $40.46 apiece today after the FDA rejected its Abbreviated New Drug Application for the generic version of GlaxoSmithKline‘s (NYSE:GSK) Advair Diskus. The Canonsburg, Penn.-based company said it is “in the process of reviewing this response and will provide an update on its application as soon as practicable once it has completed its review and discussed the FDA’s feedback with the agency.” Get the full story at our sister site, Drug Delivery Business News. The post Mylan shares down -3% after FDA rejects Advair generic appeared first on MassD...
Source: Mass Device - March 29, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Clearance Respiratory Wall Street Beat GlaxoSmithKline plc Mylan Source Type: news

FDA, Mylan silence on generic Advair may be good news for GSK
LONDON (Reuters) - A deadline for U.S. regulators to give a verdict on a generic copy of GlaxoSmithKline's blockbuster inhaled lung drug Advair has passed with no sign of approval, sparking speculation that a threat to GSK profits might be delayed. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AirDuo RespiClick Inhalation Powder (Fluticasone Propionate and Salmeterol) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2017 Category: Drugs & Pharmacology Source Type: news

As Teva Wins U.S. Approval for GSK Advair Copy, Main Fight Yet to Come As Teva Wins U.S. Approval for GSK Advair Copy, Main Fight Yet to Come
Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair inhaler, although the real battle is still to come.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 31, 2017 Category: Allergy & Immunology Tags: Pulmonary Medicine News Alert Source Type: news

Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AirDuo RespiClick (fluticasone propionate and salmeterol... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 30, 2017 Category: Drugs & Pharmacology Source Type: news

As Teva wins U.S. approval for GSK Advair copy, main fight yet to come
LONDON (Reuters) - Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair inhaler, although the real battle is still to come. (Source: Reuters: Health)
Source: Reuters: Health - January 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Advair HFA (Fluticasone Propionate and Salmeterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Advair Diskus, Advair HFA (fluticasone and salmeterol oral inhaler)
Title: Advair Diskus, Advair HFA (fluticasone and salmeterol oral inhaler)Category: MedicationsCreated: 1/22/2002 12:00:00 AMLast Editorial Review: 11/7/2016 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - November 7, 2016 Category: Respiratory Medicine Source Type: news

AstraZeneca, Bespak ink deal for metered-dose inhaler
AstraZeneca (NYSE:AZN) said last week that it inked a multi-year commercial supply deal with Consort Medical (LON:CSRT) subsidiary Bespak for its pressurized metered-dose inhaler technology. Bespak will supply inhaler valves and actuators for use with AstraZeneca’s inhaled aerosol treatment for chronic obstructive pulmonary disease. AstraZeneca won FDA approval in April for the aerosol, Bevespi Aerosphere (glycophrrolate and formoterol fumarate), indicated for long-term, maintenance therapy in patients with COPD. “We are delighted to have successfully concluded this agreement with AstraZeneca,” Consort Me...
Source: Mass Device - September 12, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Research & Development AstraZeneca plc Consort Medical Source Type: news

Advair Safety on Par With Monotherapy for Kids With Asthma (CME/CE)
(MedPage Today) -- But do all children benefit from combination therapy with a LABA? (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - August 31, 2016 Category: Allergy & Immunology Source Type: news

Novel LAMA/LABA Combo Shines for COPD (CME/CE)
(MedPage Today) -- Better than Advair for some measures in phase III trial (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - August 20, 2016 Category: Allergy & Immunology Source Type: news

Your inhaler’s watching you: drugmakers race for smart devices
(Reuters) – Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly. Linked wirelessly to the cloud, the gadgets are part of a medical “Internet of Things” that promises improved adherence, or correct use of the medication, and better health outcomes. They may also hold the key to company profits in an era of increasingly tough competition. Drugmakers believe giving patients and doctors the ability to check inhaler use in this way could be a big help in proving the value of thei...
Source: Mass Device - July 20, 2016 Category: Medical Equipment Authors: MassDevice Tags: mHealth (Mobile Health) Patient Monitoring Respiratory AstraZeneca plc GlaxoSmithKline plc Novartis AG Qualcomm Source Type: news

Your inhaler ’ s watching you: drugmakers race for smart devices
(Reuters) – Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly. Linked wirelessly to the cloud, the gadgets are part of a medical “Internet of Things” that promises improved adherence, or correct use of the medication, and better health outcomes. They may also hold the key to company profits in an era of increasingly tough competition. Drugmakers believe giving patients and doctors the ability to check inhaler use in this way could be a big help in proving the value of thei...
Source: Mass Device - July 20, 2016 Category: Medical Equipment Authors: MassDevice Tags: mHealth (Mobile Health) Patient Monitoring Respiratory AstraZeneca plc GlaxoSmithKline plc Novartis AG Qualcomm Source Type: news

Strong earnings help Consort Medical recover from hit by delay in Mylan approval
Consort Medical (LON:CSRT) said the impending launch of a generic Advair inhaler by Mylan (NSDQ:MYL) represents a significant opportunity for its Bespak drug delivery device unit, but analysts were less impressed after the FDA delayed its decision date for asthma therapy to March 28, 2017. That pushed CSRT shares down -1.9% to a $1.35 (941 pence) close yesterday on the London Stock Exchange, but investors pushed the stock up 4.9% to a $1.41 (987p) close today after Consort said it doubled the top line in fiscal 2016. Sales were up 50% to $396.4 million (£276.9 million) and pretax ea...
Source: Mass Device - June 17, 2016 Category: Medical Equipment Authors: Varun Saxena Tags: Drug-Device Combinations Pharmaceuticals Respiratory Asthma Consort Medical Mylan Inc. Source Type: news

In fight for GSK's Advair, generic firms step carefully on price
LONDON (Reuters) - Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Advair Diskus (Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 23, 2016 Category: Drugs & Pharmacology Source Type: news

fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFA
Title: fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFACategory: MedicationsCreated: 1/22/2002 12:00:00 AMLast Editorial Review: 5/18/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 18, 2016 Category: Drugs & Pharmacology Source Type: news

LABA-LAMA Combo Tops Advair for Cutting COPD Flares (CME/CE)
(MedPage Today) -- Once-daily version of Utibron wins in head-to-head trial (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - May 16, 2016 Category: Geriatrics Source Type: news

Asthma Patients Treated Safely with Salmeterol-Fluticasone Combo
An FDA-mandated study finds use of LABA plus ICS in a single inhaler noninferior to ICS alone with regard to serious asthma outcomes. (Source: ConsultantLive)
Source: ConsultantLive - May 9, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Asthma Source Type: news

No Greater Risk of Serious Asthma Events With Advair (CME/CE)
(MedPage Today) -- But combo treatment not necessarily safe for all asthma patients (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 7, 2016 Category: Allergy & Immunology Source Type: news

Fluticasone-Salmeterol Noninferior to Fluticasone for Serious Asthma Events (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Fluticasone plus salmeterol is noninferior to fluticasone monotherapy in the risk for serious asthma-related events, finds an industry-conducted study in the New England Journal of … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 7, 2016 Category: Primary Care Source Type: news

AAAAI: Risks comparable in adult asthma patients given fluticasone and salmeterol plus fluticasone combo
LOS ANGELES – Fluticasone-salmeterol inhalers (Advair) are as safe as and more effective than fluticasone monotherapy inhalers are for patients with moderate to severe asthma, according to a large,... (Source: Family Practice News)
Source: Family Practice News - March 6, 2016 Category: Primary Care Source Type: news

AAAAI: Risks comparable in adult asthma patients given fluticasone and salmeterol plus fluticasone combo
LOS ANGELES – Fluticasone-salmeterol inhalers (Advair) are as safe as and more effective than fluticasone monotherapy inhalers are for patients with moderate to severe asthma, according to a large,... (Source: Pediatric News)
Source: Pediatric News - March 6, 2016 Category: Journals (General) Source Type: news

U.S. copy of GSK's Advair a step closer as Mylan files generic version
LONDON (Reuters) - The arrival of cheap generic versions of GlaxoSmithKline's top-selling lung drug Advair has moved a step closer with confirmation from Mylan that it has submitted a generic version for approval. (Source: Reuters: Health)
Source: Reuters: Health - January 12, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

New Sandoz patient-centric inhaler now available to treat adults with COPD
Novel inhaler approved for adults with chronic obstructive pulmonary disease (COPD) (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 24, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Respiratory Patient care AirFluSal copd fluticasone propionate Forspiro inhaler Latest News salmeterol Seretide Accuhaler treatment adherence Source Type: news

GSK plan to file up to 20 new drugs by 2020 underwhelms market
LONDON (Reuters) - GlaxoSmithKline could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalize a portfolio hit by falling sales of best-selling inhaled lung treatment Advair, the company said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - November 3, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Advair revenue down again, but GSK looks to next-gen (and Zebulon) for replacement revenue
London-based GlaxoSmithKline (NYSE: GSK) reported quarterly earnings good enough for investors to trade the stock up more than 2 percent Wednesday. In the Triangle, however, those with a keen eye on the drug giant looked more closely at Advair, which again reported declining revenue. For the first half of 2015, GSK reported $1.37 billion in U.S. sales for Advair, an asthma drug, a figure down 19 percent from last year. The Triangle focuses on Advair because GSK leans heavily on its plant in Zebulon… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 29, 2015 Category: Biotechnology Authors: Jason deBruyn Source Type: news

FDA cracks down on 1,000 illegal online medicine sellers
(Reuters) — The FDA said yesterday it had sent warning letters and seized potentially dangerous, unapproved medicines and medical devices from more than 1,050 websites globally. Inspectors from the FDA and other federal agencies screened and seized illegal drugs and medical devices received through international mail facilities in Chicago, Miami and New York, the FDA said in a statement. The health regulator said it sent warning letters to operators of nearly 400 websites and to 9 firms distributing unapproved medical devices online. The prescription drugs targeted included some purported to be the generic ...
Source: Mass Device - June 19, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Business/Financial News Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

Cipla expects to double sales of respiratory drugs by 2020
Cipla is building up its respiratory drug portfolio. Seroflo, a generic version of GSK Plc's inhaler Advair, is one of its biggest bets in that segment. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 17, 2015 Category: Pharmaceuticals Source Type: news

Adding a LAMA to Salmeterol/Fluticasone Improves COPD Lung FunctionAdding a LAMA to Salmeterol/Fluticasone Improves COPD Lung Function
Adding a once-a-day long-acting muscarinic antagonist (LAMA) to salmeterol/fluticasone propionate (SAL/FP) improves outcomes in chronic obstructive pulmonary disease (COPD), according to a report from Australia and New Zealand. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 8, 2015 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

GSK sees little prospect of U.S. generic Advair in 2016
LONDON (Reuters) - After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics - but not just yet. (Source: Reuters: Health)
Source: Reuters: Health - May 6, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

How Medicare contributed to GSK's top line (Hint: Advair)
Medicare spent $2.26 billion on GlaxoSmithKline's (NYSE: GSK) asthma drug, Advair Diskus, in 2013, making it the second-costliest drug for the government payer in 2013. More than 1.5 million beneficiaries filed 6.6 million claims for the inhalable dry powder that comes in the plastic purple dispensing device. Large portions of the drug and the device are produced in Zebulon. For the first time, Medicare publicly released detailed information on the prescription drugs that health providers prescribed… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 1, 2015 Category: American Health Authors: Jason deBruyn Source Type: news

Lupin and Celon Pharma partner for generic version of GSK’s Advair Diskus
India-based drugmaker Lupin has signed an agreement with Polish biopharmaceutical firm Celon Pharma to develop a fluticasone / salmeterol dry powder inhaler (DPI). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 18, 2015 Category: Pharmaceuticals Source Type: news

Mylan to start Phase III trial of generic Advair Diskus, insulin analogue to Lantus
Global generic and specialty pharmaceuticals company Mylan is set to start a Phase III clinical trial of its generic version of GlaxoSmithKline's (GSK) Advair Diskus and its insulin analogue to Sanofi's Lantus. (Source: Drug Development Technology)
Source: Drug Development Technology - September 16, 2014 Category: Pharmaceuticals Source Type: news

Novartis data show once-daily Ultibro® Breezhaler® is superior in COPD
Novartis presented new data that demonstrated once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and improving lung function compared to twice-daily Seretide®Accuhaler®* (salmeterol/fluticasone (SFC)), in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 8, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Industry News Respiratory copd exacerbation indacaterol/glycopyrronium bromide Latest News lung function Source Type: news

Cipla introduces Serroflo for respiratory treatment in Germany and Sweden
India-based Cipla has introduced Serroflo (salmeterol/fluticasone MDI) in Germany and Sweden to treat patients suffering from asthma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 2, 2014 Category: Pharmaceuticals Source Type: news